Literature DB >> 9731200

Human dynamin-like protein interacts with the glycogen synthase kinase 3beta.

Y R Hong1, C H Chen, D S Cheng, S L Howng, C C Chow.   

Abstract

Members of the dynamin superfamily are implicated in vesicle trafficking. Using human glycogen synthase kinase 3 beta (Gsk-3 beta) as bait in the yeast two-hybrid system, we identified a novel human dynamin-like protein IV (HdynIV). When the full-length cDNA of HdynIV was sequenced, it showed that HdynIV's carboxyl terminal lacks a proline-rich domain that can bind to Gsk-3 beta. By Northern blot analysis and isoform-specific PCR, we found that HdynIV is expressed ubiquitously in all human tissues examined. Two transcripts of 2.4 and 4.4 kb are shown to be more abundant in heart, brain, and skeletal muscle. Interestingly, the 2.4-kb transcript is expressed more distinctly in the fetal liver than in the adult liver, suggesting that this protein might play a role during development. In the present report, we have demonstrated that HdynIV interacts with the Gsk-3 beta through its carboxyl-terminal region, implying than HdynIV may also be involved in cell signaling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731200     DOI: 10.1006/bbrc.1998.9253

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Mitochondrial Perturbation in Alzheimer's Disease and Diabetes.

Authors:  F Akhter; D Chen; S F Yan; S S Yan
Journal:  Prog Mol Biol Transl Sci       Date:  2017-02-04       Impact factor: 3.622

2.  High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission.

Authors:  Tianzheng Yu; Bong Sook Jhun; Yisang Yoon
Journal:  Antioxid Redox Signal       Date:  2010-08-23       Impact factor: 8.401

3.  Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.

Authors:  Urmi Sengupta; Sanchaita Ukil; Nevenka Dimitrova; Shipra Agrawal
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

4.  Involvement of the residues of GSKIP, AxinGID, and FRATtide in their binding with GSK3beta to unravel a novel C-terminal scaffold-binding region.

Authors:  Shen-Long Howng; Chi-Ching Hwang; Chia-Yi Hsu; Meng-Yu Hsu; Chun-Yen Teng; Chia-Hua Chou; Mei-Feng Lee; Chia-Hung Wu; Shean-Jaw Chiou; Ann-Shung Lieu; Joon-Khim Loh; Chia-Ning Yang; Chan-Shing Lin; Yi-Ren Hong
Journal:  Mol Cell Biochem       Date:  2009-12-31       Impact factor: 3.396

Review 5.  Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2015-12-17

6.  Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998).

Authors:  T P Loughran; L Zickl; T L Olson; V Wang; D Zhang; H L M Rajala; Z Hasanali; J M Bennett; H M Lazarus; M R Litzow; A M Evens; S Mustjoki; M S Tallman
Journal:  Leukemia       Date:  2014-09-13       Impact factor: 11.528

7.  GSK-3: Functional Insights from Cell Biology and Animal Models.

Authors:  Oksana Kaidanovich-Beilin; James Robert Woodgett
Journal:  Front Mol Neurosci       Date:  2011-11-16       Impact factor: 5.639

8.  Drp1-mediated mitochondrial abnormalities link to synaptic injury in diabetes model.

Authors:  Shengbin Huang; Yongfu Wang; Xueqi Gan; Du Fang; Changjia Zhong; Long Wu; Gang Hu; Alexander A Sosunov; Guy M McKhann; Haiyang Yu; Shirley ShiDu Yan
Journal:  Diabetes       Date:  2014-11-20       Impact factor: 9.461

9.  GSK3beta-mediated Drp1 phosphorylation induced elongated mitochondrial morphology against oxidative stress.

Authors:  Chia-Hua Chou; Ching-Chih Lin; Ming-Chang Yang; Chih-Chang Wei; Huei-De Liao; Run-Chin Lin; Wen-Yu Tu; Tsung-Chieh Kao; Ching-Mei Hsu; Jiin-Tsuey Cheng; An-Kuo Chou; Chu-I Lee; Joon-Khim Loh; Shen-Long Howng; Yi-Ren Hong
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.